GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » Enterprise Value

Omega Therapeutics (Omega Therapeutics) Enterprise Value : $175.69 Mil (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Omega Therapeutics's Enterprise Value is $175.69 Mil. Omega Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-94.89 Mil. Therefore, Omega Therapeutics's EV-to-EBIT ratio for today is -1.85.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Omega Therapeutics's Enterprise Value is $175.69 Mil. Omega Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-87.61 Mil. Therefore, Omega Therapeutics's EV-to-EBITDA ratio for today is -2.01.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Omega Therapeutics's Enterprise Value is $175.69 Mil. Omega Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $4.94 Mil. Therefore, Omega Therapeutics's EV-to-Revenue ratio for today is 35.57.


Omega Therapeutics Enterprise Value Historical Data

The historical data trend for Omega Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics Enterprise Value Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
- - 336.04 172.40 220.99

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 217.24 314.41 160.46 220.99 268.90

Competitive Comparison of Omega Therapeutics's Enterprise Value

For the Biotechnology subindustry, Omega Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omega Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's Enterprise Value falls into.



Omega Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Omega Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Omega Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omega Therapeutics  (NAS:OMGA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Omega Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=175.686/-94.893
=-1.85

Omega Therapeutics's current Enterprise Value is $175.69 Mil.
Omega Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.89 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Omega Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=175.686/-87.613
=-2.01

Omega Therapeutics's current Enterprise Value is $175.69 Mil.
Omega Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.61 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Omega Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=175.686/4.939
=35.57

Omega Therapeutics's current Enterprise Value is $175.69 Mil.
Omega Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omega Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Omega Therapeutics (Omega Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
20 Acorn Park Drive, Cambridge, MA, USA, 02140
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.
Executives
Michelle C Werner director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young director, 10 percent owner C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed officer: Chief Financial Officer C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus officer: Chief Human Resources Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng officer: See Remarks C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore officer: Chief Medical Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney officer: Chief Financial Officer C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Omega Therapeutics (Omega Therapeutics) Headlines

From GuruFocus